Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

Melinda Biernacki, Agie Cole, Kausar Abukar, Isatou Barrow, Lorenzo Iovino, Natalie Wuliji, Mohamed Sorror, Erik Kimble, Edus Warren, Ryan Cassaday, Jordan Gauthier, Meredith Durbin, Alexandre Hirayama, Brian Till, Aude Chapuis, Filippo Milano, Lawrence Fong, Mazyar Shadman, Folashade Otegbeye

Blood (2025) 146 (Supplement 1): 6202.

https://doi.org/10.1182/blood-2025-6202

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Ryan Lynch, Christina Poh, Mazyar Shadman, Brian Till, Mengyang Di, Chaitra Ujjani, Vikram Raghunathan, Stephen Smith, David Maloney, Daria Gausman, Heather Rasmussen, David Russler-Germain, Todd Fehniger, David Kurtz, Ash Alizadeh, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2025-3591

Published: 2025

Journal Articles

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Christine Ryan, Victoria Wang, Mitchell Smith, Brian Till, Samir Parekh, David Yang, Lale Kostakoglu, Nizar Abdel Samad, Opeyemi Jegede, Richard Little, Jonathan Friedberg, John Leonard, Brad Kahl, Peter Martin

Blood (2025) 146 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2025-3581

Published: 2025

Journal Articles

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Jennifer Huang, Laura Samples, Ted Gooley, Margo Fredericks, Stephanie Louie, Grace Bishop, Christine Crider, Mehrdad Azar, Neena Kennedy, Mengyang Di, Stephen Smith, Brian Till, Ajay Gopal, Ryan Lynch, Chaitra Ujjani, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2025-2136

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Mengyang Di, Qian Wu, Ryan Lynch, Stephen Smith, Mazyar Shadman, Paul Martin, Brian Till, Neena Kennedy, Chaitra Ujjani, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2025-5394

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

Real-world barriers to treatment access in T-cell lymphoma

Bryce Bowler, Jenna Voutsinas, Qian Wu, Maya Krishnan, Dhruv Mistry, Grace Sun, Mazyar Shadman, Brian Till, Ryan Lynch, Vikram Raghunathan, Chaitra Ujjani, Stephen Smith, Mengyang Di, Paul Martin, Ajay Gopal, Christina Poh

Blood (2025) 146 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2025-4491

Published: 2025

Journal Articles

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Blood (2023) 141 (21): 2576–2586.

https://doi.org/10.1182/blood.2022019254

Published: 2023

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Real-world barriers to treatment access in T-cell lymphoma

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only